Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.54 |
| ▸ | ACE | P12821 | 2/20 | 0.47 |
| ▸ | CPA1 | P15085 | 2/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP7 | P09237 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9831516 | 0.88 | MME (0.50) | MMECTSLCTSBCTSSCTSK | |
| SCHEMBL27693745 | 0.86 | MME (0.53) | MMEACECPA1ACE2CTSL | |
| SCHEMBL27675065 | 0.84 | MME (0.47) | MMECTSLCTSBCTSSCTSK | |
| SCHEMBL9829010 | 0.83 | CTSL (0.51) | MMECTSLCTSBCTSSCTSK | |
| SCHEMBL7434243 | 0.82 | MME (0.47) | MMECTSLCTSBCTSSCTSK | |
| SCHEMBL7275108 | 0.80 | MME (0.47) | MME | |
| SCHEMBL1524821 | 0.79 | CTSK (0.52) | MMECTSLCTSBCTSSCTSK | |
| SCHEMBL30414758 | 0.77 | MME (0.52) | MMEACECPA1ACE2CTSL | |
| SCHEMBL27635504 | 0.77 | MME (0.53) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL10443832 | 0.76 | MME (0.40) | MMECTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673333-B1 | COMPRISING A FIRST GD(III) ION BOUND TO A FIRST CHELATOR; GD(III) ION HAS COORDINATION ATOMS IN AT LEAST 7 COORDINATION SITES; BOUND TO TUMOR ASSOCIATED ACTIVATIVLE GUARDING MOIETY | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2004-01-06 | — | — | US | disclosed |
| US-20030021750-A1 | Novel functional agents for magnetic resonance imaging | METAPROBE, INC. | 2003-01-30 | — | — | US | disclosed |
| EP-1278552-A2 | FUNCTIONAL MRI AGENTS FOR CANCER IMAGING | RESEARCH CORPORATION TECHNOLOGIES (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001082976-A2 | FUNCTIONAL MRI AGENTS FOR CANCER IMAGING | RESEARCH CORPORATION TECHNOLOGIES (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030021750-A1 | Novel functional agents for magnetic resonance imaging | FABP7, RXFP1, MRGPRX2 | MME 831/4885ACE 4284/4885CPA1 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.